HIV

Photo
27.01.2023 • News

J&J Ends Mosaico HIV Vaccine Trial on poor Results

Johnson & Johnson’s pharmaceuticals subsidiary Janssen is walking away from plans to launch an HIV vaccine in the immediate future after the data safety monitoring board for its latest Phase 3 trial found that the shot was no better than a placebo.

Top-Feature

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Photo
Bayer AG